1. Home
  2. CTNT vs IMMP Comparison

CTNT vs IMMP Comparison

Compare CTNT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheetah Net Supply Chain Service Inc.

CTNT

Cheetah Net Supply Chain Service Inc.

HOLD

Current Price

$0.16

Market Cap

53.5M

Sector

N/A

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.58

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTNT
IMMP
Founded
2016
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
58.2M
IPO Year
2023
2012

Fundamental Metrics

Financial Performance
Metric
CTNT
IMMP
Price
$0.16
$0.58
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
6.4M
19.6M
Earning Date
05-04-2026
04-23-2026
Dividend Yield
N/A
N/A
EPS Growth
57.74
N/A
EPS
N/A
N/A
Revenue
$1,288,536.00
N/A
Revenue This Year
$42.49
$417.85
Revenue Next Year
$22.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
182.69
N/A
52 Week Low
$0.14
$0.29
52 Week High
$2.12
$3.53

Technical Indicators

Market Signals
Indicator
CTNT
IMMP
Relative Strength Index (RSI) 19.13 37.74
Support Level N/A N/A
Resistance Level $1.58 $1.75
Average True Range (ATR) 0.20 0.07
MACD -0.12 0.11
Stochastic Oscillator 1.27 38.24

Price Performance

Historical Comparison
CTNT
IMMP

About CTNT Cheetah Net Supply Chain Service Inc.

Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: